More and more companies are looking for novel ways to educate both eye-care professionals and patients about AMD. Here are some of the newer resource materials available.
About 85% to 90% of the cases of macular degeneration are the “dry” (atrophic) type. To date, there are no approved pharmacologic treatments for the dry form of AMD, but there are several studies under way.
The past year had its share of groundbreaking research in age-related macular degeneration (AMD). Here is a brief overview of what’s been presented or published within the past 12 months.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
